Compass Therapeutics (CMPX) Total Current Liabilities (2018 - 2026)

Compass Therapeutics has reported Total Current Liabilities for 9 years, with the latest figure at $10.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 31.01% year-over-year to $10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (down 31.01% YoY) and the FY2025 annual result came in at $14.0 million, up 57.4% from the prior year.
• Total Current Liabilities slipped to $10.3 million in Q1 2026 per CMPX's latest filing, from $14.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $16.2 million in Q4 2022 and troughed at $3.9 million in Q1 2024.
• A 5-year average of $10.3 million and a median of $9.7 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 65.21% in 2024, then surged 282.74% in 2025.
• Over 5 years, Total Current Liabilities stood at $16.2 million in 2022, then slumped by 51.75% to $7.8 million in 2023, then gained by 13.75% to $8.9 million in 2024, then surged by 57.4% to $14.0 million in 2025, then fell by 26.41% to $10.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $10.3 million, $14.0 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.